GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (FRA:RPD) » Definitions » Cash Receipts from Operating Activities

Royalty Pharma (FRA:RPD) Cash Receipts from Operating Activities


View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma Cash Receipts from Operating Activities?

Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Royalty Pharma (FRA:RPD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (FRA:RPD) » Definitions » Cash Receipts from Operating Activities
Traded in Other Exchanges
Address
110 East 59th Street, FL 33, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.